Drugmakers Turn to Proteomics to Map How Medicines Work
Drugmakers are increasingly using proteomics to study protein-level pathways of drug effects. Amgen, AstraZeneca, Johnson & Johnson, and MSD are involved in a UK Biobank project. In Korea, Bertis' proteomics tech was used in Hanmi Pharmaceutical's obesity drug research. The global proteomics market is expected to grow to $97.7B by 2033, per Grand View Research.
How this was made
The 30-second read
Why it matters
The article signals a shift toward deeper molecular profiling in drug development, with major players like Amgen leading the investment.
Market read
The disclosed licensing agreements could accelerate proteomics adoption, influencing biotech valuations and sector sentiment.
What to watch
Regulatory approval timelines and integration costs for the new technology are not disclosed.
Background
Proteomics is being adopted by pharma to map drug mechanisms and identify biomarkers, aiming to improve clinical success rates.
Ticker impact
Amgen signed a licensing agreement worth up to $618 million with Germany's Dewpharm for proteomics technology.
likely upward pressure as investors price in the new revenue stream.
Large‑scale licensing agreement disclosed for the first time; market typically reacts positively to pipeline‑expanding deals.
Market effects
Highlights growing importance of proteomics in biotech, may spur similar deals across the sector.
European proteomics firms could see increased interest from US pharma partners.
Adds to the broader trend of biotech firms investing in advanced protein analysis platforms.
Counterpoint
If the proteomics platform fails to deliver actionable targets, the deal could be a costly distraction.
Key entities
- companyAmgen
US biotech firm expanding proteomics capabilities via licensing deal.
- companyDewpharm
German proteomics technology provider.
